Biospectal announces public beta launch of optiBP for Android at CES 2021

Biospectal, the remote patient monitoring and biosensing software company, announced the public beta launch of Biospectal OptiBP for Android as part of the SWISS Pavilion at the all-digital 2021 Consumer Electronics Show (CES).

Backed by grants from the Bill & Melinda Gates FoundationGrand Challenges Canada and Innosuisse, Biospectal OptiBP empowers people worldwide with a medical-grade device that integrates directly into the ubiquitous smartphone already in their pocket, enabling instantaneous blood pressure measurement and monitoring, anytime and anywhere. View a short video of how Biospectal OptiBP works here.

According to the CDC, hypertension affects nearly 46% or 100M US adults, while the World Health Organization estimates 1.13Bn people worldwide have hypertension. Dubbed the “silent killer,” only one in five people afflicted with hypertension have control over the condition. People need an easy to use, digital means to accurately measure, monitor, track and share their blood pressure data with their doctors; a need that the onset of COVID-19 and demand for telehealth solutions has only amplified.

Eliott Jones

“Democratising and providing easy access to blood pressure monitoring to people worldwide enables improved treatment and impacts medical outcomes. Biospectal OptiBP is a prime example of a broader transition toward remote patient monitoring that moves the clinical functions and capability out of the professional setting to the ‘point of patient’ where they live,” says Eliott Jones, CEO of Biospectal.

“Biospectal’s patented OptiBP technology replaces the antiquated traditional blood pressure cuff and provides medical-grade blood pressure measurement and management at the ‘point of patient’ in the time it takes to download an app without the need for yet another wearable device or additional bulky hardware. Health-conscious consumers and hypertensive patients worldwide can now contribute to, and be involved in their health outcomes in a way that hasn’t existed previously.”

How Biospectal optiBP works.

The Biospectal OptiBP app runs on a typical smartphone and uses the built-in camera to record and measure a user’s blood flow via their fingertip quickly and easily. A measurement is rendered in approximately 20 seconds half the time of a typical blood pressure cuff.

Biospectal’s proprietary algorithms and optical signal capture methods then transform the captured data into blood pressure values. With Biospectal’s software solutions, anyone in the world with a smartphone can turn their device into a connected, smart, clinical-grade monitor in the time it takes to download and install an app.

Additionally, the captured blood pressure data connects seamlessly with a user’s clinicians to support treatment regimens that help improve health, longevity and quality of life. Key benefits include:

  • Connected remote patient monitoring shortens the pathway from measurement to action in a clinical regimen;
  • Ease of use with an existing, ubiquitous device the smartphone removes adherence barriers;
  • Allows users to measure and monitor their blood pressure in their ‘natural’ environment, which is ideally where blood pressure should be monitored;
  • App form factor offers continuous product improvement and feature updates; and
  • Unprecedented data insights via global device network drives higher value for drug development and lower insurance costs.

A recent large-scale, third-party clinical research study published by Scientific Reports in Nature validated the ability of the Biospectal OptiBP smartphone app to accurately measure blood pressure utilising transdermal optical sensing and a smartphone camera lens. No other blood pressure monitoring and management device on the market offers both the medical-grade accuracy and convenience of Biospectal.

“For low and middle-income countries around the globe, this type of technology is a game changer in the fight against non-communicable diseases, dominated by hypertension and cardiovascular disease,” says Prof. Alain Labrique, director of the Johns Hopkins Global mHealth Initiative and associate chair for Research. “For the billions of people living in remote, rural communities, having access to accurate blood pressure readings will enable early diagnosis and hopefully, treatment preventing illness and loss of life.”

Biospectal trained its software algorithm using over two million resulting invasively acquired blood pressure samples recorded in the operating room of the CHUV in partnership with the Swiss Center for Electronics and Microtechnology (CSEM), and then validated it with outpatients in the hypertension clinic CHUV. The company’s patented technology represents 10+ years of non-invasive optical biosensing R&D led by Biospectal chief medical advisor, Dr. Patrick Schoettker, M.D..

The Biospectal OptiBP for Android public beta is available now in the US, UK, France, Germany, Spain and Switzerland. Interested participants can register for the public beta here or sign up to be notified once Biospectal OptiBP becomes available in their country. Contact biospectal@wearemgp.com to set up a meeting at CES, January 11 – 14, 2021 or access the press kit here.

Comment on this article below or via Twitter: @IoTNow_OR @jcIoTnow

FEATURED IoT STORIES

9 IoT applications that will change everything

Posted on: September 1, 2021

Whether you are a future-minded CEO, tech-driven CEO or IT leader, you’ve come across the term IoT before. It’s often used alongside superlatives regarding how it will revolutionize the way you work, play, and live. But is it just another buzzword, or is it the as-promised technological holy grail? The truth is that Internet of

Read more

Which IoT Platform 2021? IoT Now Enterprise Buyers’ Guide

Posted on: August 30, 2021

There are several different parts in a complete IoT solution, all of which must work together to get the result needed, write IoT Now Enterprise Buyers’ Guide – Which IoT Platform 2021? authors Robin Duke-Woolley, the CEO and Bill Ingle, a senior analyst, at Beecham Research. Figure 1 shows these parts and, although not all

Read more

CAT-M1 vs NB-IoT – examining the real differences

Posted on: June 21, 2021

As industry players look to provide the next generation of IoT connectivity, two different standards have emerged under release 13 of 3GPP – CAT-M1 and NB-IoT.

Read more

IoT and home automation: What does the future hold?

Posted on: June 10, 2020

Once a dream, iot home automation is slowly but steadily becoming a part of daily lives around the world. In fact, it is believed that the global market for smart home automation will reach $40 billion by 2020.

Read more
RECENT ARTICLES

CloudM announces Archive feature which save businesses time and money while meeting compliance demands

Posted on: October 26, 2021

CloudM, a SaaS data management platform, has announced the launch of Archive, a new feature which allows users to easily, automatically, and safely store and recover user data, helping businesses to remain compliant without facing the mounting user license fees associated with traditional archiving and ediscovery solutions.

Read more

The shortlist nominees for the 2021 IoT Global Awards are …

Posted on: October 26, 2021

WeKnow Media Ltd, the award organisers, are pleased to announce the Shortlisted Entries for the 2021 IoT Global Awards. “The pandemic and global economic shock might have been expected to slow the growth of IoT-enabled services. Not so, if we’re to judge from entries to the IoT Global Awards 2021,” says Jeremy Cowan, chairman of the

Read more